| Literature DB >> 21483652 |
Yuqing Lou1, Jielin Liu, Yao Li, Ya Liu, Zuoguang Wang, Kuo Liu, Hai Wu, Qiuli Niu, Wei Gu, Yanhong Guo, Zhizhong Li, Shaojun Wen.
Abstract
BACKGROUND: The β2-adrenergic receptor (ADRB2) gene has been widely researched as a candidate gene for essential hypertension (EH), but no consensus has been reached in different ethnicities. The aim of the present study was to evaluate the possible association between the ADRB2 gene polymorphisms and the EH risk in the Northern Han Chinese population. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2011 PMID: 21483652 PMCID: PMC3071737 DOI: 10.1371/journal.pone.0018590
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of study participants.
| Hypertension | Normotension | ||
| (n = 747) | (n = 390) | P | |
| gender, M/F | 479/268 | 233/157 | NS |
| age(years) | 51.52±9.46 | 51.02±7.66 | NS |
| SBP(mmHg) | 153.41±19.65 | 114.33±11.07 | <0.001 |
| DBP(mmHg) | 99.18±14.20 | 74.04±8.26 | <0.001 |
| BMI(kg/m2) | 26.88±3.45 | 24.90±3.20 | <0.001 |
| TC(mmol/L) | 5.56±2.98 | 5.13±1.07 | <0.001 |
| HDL-C(mmol/L) | 1.26±0.62 | 1.44±1.17 | 0.006 |
| LDL-C(mmol/L) | 3.38±0.87 | 3.45±0.78 | NS |
| TG(mmol/L) | 2.11±1.36 | 1.69±1.05 | <0.001 |
| Glu(mmol/L) | 5.38±0.61 | 5.08±0.59 | <0.001 |
| Cr(µmol/L) | 78.97±18.70 | 77.67±14.68 | NS |
| ALT(U/L) | 25.62±13.19 | 24.48±12.44 | NS |
| HR(bpm) | 71.30±9.61 | 70.73±9.20 | NS |
| Smokers(n) | 193 | 102 | NS |
| Drinkers(n) | 223 | 53 | <0.001 |
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; Glu, glucose; Cr, creatinine; ALT, alanine aminotransferase; HR, heart rate.
Values are mean±SD.
NS indicates not significant.
The frequencies of the β2-adrenergic receptor gene C-47T, A46G and C79G polymorphisms genotypes.
| Genotype (frequency,%) | P | Allele (frequency,%) | P | |||||
| C-47T | TT | CT | CC | T allele | C allele | |||
| Case (Total) | 571(77.2) | 163(22.0) | 6(0.8) | 1305(88.2) | 175(11.8) | |||
| Control (Total) | 314(80.7) | 68(17.5) | 7(1.8) | 0.358 | 696(89.5) | 82(10.5) | 0.361 | |
| Case (Male) | 371(78.3) | 100(21.1) | 3(0.6) | 842(88.8) | 106(11.2) | |||
| Control (Male) | 187(80.6) | 41(17.7) | 4(1.7) | 0.723 | 415(89.4) | 49(10.6) | 0.726 | |
| Case (Female) | 200(75.2) | 63(23.7) | 3(1.1) | 463(87.0) | 69(13.0) | |||
| Control (Female) | 127(80.9) | 27(17.2) | 3(1.9) | 0.289 | 281(89.5) | 33(10.5) | 0.288 | |
| A46G | AA | AG | GG | A allele | G allele | |||
| Case (Total) | 208(28.3) | 369(50.2) | 158(21.5) | 785(53.4) | 685(46.6) | |||
| Control (Total) | 143(37.3) | 174(45.4) | 66(17.2) | 0.003 | 460(60.1) | 306(39.9) | 0.003 | |
| Case (Male) | 135(28.8) | 239(51.0) | 95(20.3) | 509(54.3) | 429(45.7) | |||
| Control (Male) | 94(40.9) | 98(42.6) | 38(16.5) | 0.006 | 286(62.2) | 174(37.8) | 0.005 | |
| Case (Female) | 73(27.4) | 130(48.9) | 63(23.7) | 276(51.9) | 256(48.1) | |||
| Control (Female) | 49(32.0) | 76(49.7) | 28(18.3) | 0.167 | 174(56.9) | 132(43.1) | 0.164 | |
| C79G | CC | CG | GG | C allele | G allele | |||
| Case (Total) | 566(76.8) | 164(22.3) | 7(0.9) | 1296(87.9) | 178(12.1) | |||
| Control (Total) | 301(80.5) | 66(17.6) | 7(1.9) | 0.335 | 668(89.3) | 80(10.7) | 0.337 | |
| Case (Male) | 367(77.9) | 100(21.2) | 4(0.8) | 834(88.5) | 108(11.5) | |||
| Control (Male) | 185(80.4) | 41(17.8) | 4(1.7) | 0.649 | 411(89.3) | 49(10.7) | 0.650 | |
| Case (Female) | 199(74.8) | 64(24.1) | 3(1.1) | 462(86.8) | 70(13.2) | |||
| Control (Female) | 116(80.6) | 25(17.4) | 3(2.1) | 0.319 | 257(89.2) | 31(10.8) | 0.319 | |
*P value of the comparison of the additive genetic model using the generalized linear model.
**P value of the comparison of allelic frequencies.
Odds ratios of additive genetic model comparison for each single-nucleotide polymorphism genotype associated with essential hypertension in the Northern Han Chinese population.
| Overall | Male | Female | |||||
| SNP | Contrast | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| C-47T | CC vs. CT vs. TT | 1.012(0.746–1.374) | 0.940 | 0.910(0.611–1.355) | 0.642 | 1.156(0.709–1.887) | 0.560 |
| A46G | GG vs. AG vs. AA | 1.282(1.056–1.555) | 0.012 | 1.332(1.037–1.709) | 0.025 | 1.176(0.854–1.623) | 0.319 |
| C79G | GG vs. CG vs. CC | 1.032(0.760–1.401) | 0.841 | 0.956(0.645–1.418) | 0.825 | 1.138(0.692–1.873) | 0.611 |
ORs adjusted for gender, age, body mass index, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum triglyceride levels, plasma glucose level, smoking habits and drinking habits. OR, odds ratio; CI, confidence interval; SNP, single-nucleotide polymorphism.
*ORs adjusted for gender was not performed in Male and Female.
P-value for the interaction between A46G genotype and gender on hypertension was 0.617.
The genotype distributions and allele frequencies of the β2-adrenergic receptor gene C-47T, A46G and C79G polymorphisms in obese and non-obese.
| Polymorphism | Total (n = 1137) | Male (n = 712) | Female (n = 425) | |||||||||
| Obese (n = 713) | Non-obese (n = 424) | Obese (n = 487) | Non-obese (n = 225) | Obese (n = 226) | Non-obese (n = 199) | |||||||
| Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | |
| (n = 533) | (n = 180) | (n = 214) | (n = 210) | (n = 365) | (n = 122) | (n = 114) | (n = 111) | (n = 168) | (n = 58) | (n = 100) | (n = 99) | |
| C-47T | ||||||||||||
| TT (n) | 397 | 145 | 174 | 169 | 277 | 98 | 94 | 89 | 120 | 47 | 80 | 80 |
| CT (n) | 125 | 32 | 38 | 36 | 81 | 23 | 19 | 18 | 44 | 9 | 19 | 18 |
| CC (n) | 6 | 3 | 0 | 4 | 3 | 1 | 0 | 3 | 3 | 2 | 0 | 1 |
| C allele frequency | 0.130 | 0.106 | 0.090 | 0.105 | 0.120 | 0.102 | 0.084 | 0.109 | 0.150 | 0.112 | 0.096 | 0.101 |
| A46G | ||||||||||||
| AA (n) | 142 | 74 | 66 | 69 | 101 | 53 | 34 | 41 | 41 | 21 | 32 | 28 |
| AG (n) | 258 | 82 | 111 | 92 | 176 | 53 | 63 | 45 | 82 | 29 | 48 | 47 |
| GG (n) | 124 | 22 | 34 | 44 | 80 | 15 | 15 | 23 | 44 | 7 | 19 | 21 |
| G allele frequency | 0.483 | 0.354 | 0.424 | 0.439 | 0.471 | 0.343 | 0.415 | 0.417 | 0.509 | 0.377 | 0.434 | 0.464 |
| C79G | ||||||||||||
| CC (n) | 395 | 141 | 171 | 160 | 275 | 97 | 92 | 88 | 120 | 44 | 79 | 72 |
| CG (n) | 126 | 32 | 38 | 34 | 81 | 23 | 19 | 18 | 45 | 9 | 19 | 16 |
| GG (n) | 6 | 3 | 1 | 4 | 3 | 1 | 1 | 3 | 3 | 2 | 0 | 1 |
| G allele frequency | 0.131 | 0.108 | 0.095 | 0.106 | 0.121 | 0.103 | 0.094 | 0.110 | 0.152 | 0.118 | 0.097 | 0.101 |
Stratified analyses of association between the genotypes and risk of essential hypertension in the obese and the non-obese participants.
| Total | Male | Female | ||||||
| SNP | Population | Contrast | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| C-47T | Obese | CC vs. CT vs. TT | 1.300(0.861–1.961) | 0.211 | 1.138(0.672–1.923) | 0.631 | 1.727(0.850–3.509) | 0.130 |
| Non-obese | CC vs. CT vs. TT | 0.708(0.430–1.166) | 0.174 | 0.634(0.322–1.247) | 0.187 | 0.753(0.351–1.618) | 0.467 | |
| A46G | Obese | GG vs. AG vs. AA | 1.645(1.258–2.151) | <0.001 | 1.603(1.153–2.227) | 0.005 | 1.739(1.062–2.849) | 0.028 |
| Non-obese | GG vs. AG vs. AA | 0.927(0.688–1.248) | 0.616 | 0.942(0.618–1.433) | 0.777 | 0.839(0.539–1.305) | 0.436 | |
| C79G | Obese | GG vs. CG vs. CC | 1.287(0.851–1.942) | 0.232 | 1.147(0.678–1.942) | 0.609 | 1.647(0.810–3.356) | 0.169 |
| Non-obese | GG vs. CG vs. CC | 0.745(0.457–1.214) | 0.236 | 0.722(0.380–1.374) | 0.320 | 0.745(0.341–1.626) | 0.459 | |
ORs adjusted for gender, age, body mass index, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum triglyceride levels, plasma glucose level, smoking habits and drinking habits. OR, odds ratio; CI, confidence interval; SNP, single-nucleotide.
*ORs adjusted for gender was not performed in sub-group analyses of Male and Female.
P-value for the interaction between A46G genotype and body mass index on hypertension was 0.010.
Figure 1Linkage disequilibrium (LD) block defined by the Haploview program based on the confidence interval method.
a represents LD measure of D'. b represents LD measure of r2.
Haplotype analyses of the β2-adrenergic receptor gene polymorphisms in hypertension and control subjects.
| Haplotype frequency | |||||||||
| C-47T | A46G | C79G | Cases | Controls | HS test P value | OR [95% CI] | P value | OR [95% CI] | Global P value |
| T | A | C | 0.534 | 0.600 | 0.003 | 0.763 [0.639–0.912] | - | - | 0.014 |
| T | G | C | 0.345 | 0.294 | 0.015 | 1.265 [1.047–1.530] | 0.005 | 1.319 [1.085–1.604] | |
| C | G | G | 0.121 | 0.106 | 0.292 | 1.162 [0.879–1.537] | 0.089 | 1.284 [0.963–1.713] | |
All haplotypes with frequency greater than 1% detected in the haplotype analyses are shown in the table.
HS test, haplotype specific testing; OR, odds ratio; CI, confidence interval.
P values and OR values derived from comparing of a specific haplotype with the other two.
P values and OR values derived from comparing each haplotype with the base-line haplotype (T-A-C).
P value for global test comparing model with haplotypes to model without.